Regulation of estrogen/progestogen receptors in the endometrium

International Journal of Fertility and Menopausal Studies

Volumn 41, Issue 1, 1996, Pages 16-21

  Casper, Robertt ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

breakthrough bleeding; endometrium; estrogen receptors; hormonal replacement therapy; progestin receptors

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PIPERAZINE ESTRONE SULFATE; VASCULOTROPIN;

APOPTOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG WITHDRAWAL; ENDOMETRIUM ATROPHY; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; VAGINA BLEEDING;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENSTRUATION DISTURBANCES; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; POSTMENOPAUSE; PROGESTINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; UTERINE HEMORRHAGE;

EID: 0029918427     PISSN: 10693130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Ravnikar VA: Compliance with hormone replacement therapy: are women receiving the full impact of hormone replacement therapy preventative health benefits? Womens Health Issues 2:75-80, 1992.
2. Casper RF: Compliance problems with hormonal replacement. SOGC Journal 14:43-45, 1992.
3. Hulka BS, Kaufman DG, Fowler WC Jr. et al: Predominance of early endometrial cancers after long-term estrogen use. JAMA 244:241-2422, 1980.
4. Jick H, Watkins RN, Hunter JR, et al: Replacement estrogens and endometrial cancer. N Engl J Med 300:218-222, 1979.
5. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593, 1995.
6. Barbieri RL: Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy. Am J Obstet Gynecol 162:593, 1990.
7. Casper RF, Chapdelaine A: Estrogen and interrupted progestin: A new concept for menopausal hormone replacement therapy. Am J Obstet Gynecol 168:1188-1196, 1993.
8. Eckert RL, Katzenellenbogen BS: Human endometrial cells in primary tissue culture: Modulation of the progesterone receptor level by natural and synthetic estrogens in vitro. J Clin Endocrinol Metab 52:699-708, 1981.
9. Kreitmann-Gimbal B, Bayard F, Nixon WE, et al: Patterns of estrogen and progesterone receptors in monkey endometrium during the normal menstrual cycle. Steroids 35:471-79, 1980.
10. West NB, Brenner RM: Progesterone-mediated suppression of estradiol receptors in cynomolgus macaque cervix, endometrium and oviduct during sequential estradiol progesterone treatment. J Steroid Biochem 22:29-37, 1985.
11. Neumannova M, Kauppila A, Kivinen S, et al: Short-term effects of tamoxifen, medroxyprogesterone acetate, and their combination on receptor kinetics and 17ß-hydroxysteroid dehydrogenase in human endometrium. Obstet Gynecol 66:695-700, 1985.
12. Whitehead MI, Townsend FT, Pryse-Davies J, et al: Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 305:1599-1605,1981
13. Leavitt WW, Okulicz WC, McCracken JA, et al: Rapid recovery of nuclear estrogen receptor and oxytocin receptor in the ovine uterus following progesterone withdrawal. J Steroid Biochem 22:686-691, 1985.
14. Eriksen EF, Colvard DS, Berg NJ, et al: Evidence of estrogen-receptors in normal human osteoblast-like cells. Science 241:84-86, 1988.
15. Komm BS, Terpenning CM, Benz DJ, et al: E binding, receptor mRNA, and biologic response in osteoblastlike osteosarcoma cells. Science 241:81-84,1988.
16. Vanin CM, MacLusky NJ, Grynpas MD, et al: The effect of three hormone replacement regimens on bone density in the aged oophorectomized rat. Fertil Steril 63:643-651,1995.
17. Blaustein JD, Brown TJ: Progesterone decreases the concentration of hypothalamic and anterior pituitary estrogen receptors in ovariectomized rats. Brain Res 304:225-236, 1984.
18. Casper RF, Yen SSC: Neuroendocrine changes during menopausal flushes, in Norman RL (ed): Neuroendocrine Aspects of Reproduction. Academic Press, New York, pp 359-378, 1983.
19. Bullock JL, Massey FM, Gambrell RD, Jr: Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 46:165-168,1975.
20. de Lignieres B, Linares G, Barrat J: Effects of progesterone on epithelial cell mitotic activity in human breast, in Lobo RA, Naflolin F (eds): Progesterone in Hormonal Replacement Therapy. The Parthenon Publishing Group, Park Ridge, New Jersey, pp 47-56, 1992.
21. Clarke CL, Sutherland RL: Progestin regulation of cellular proliferation. Endocrine Rev 11:266-301, 1990.
22. Dupont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 151:67-72, 1991.
23. Christensen MS, Hagen C, Christiansen C, et al: Dose response evaluation of cyclic estrogen/gestagen in postmenopausal women: Placebo controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 144:873-879, 1982.
24. Weinstein L: Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol 69:929-932, 1987.
25. Prough SG, Aksel S, Wiebe RH, et al: Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 157:1449-1453, 1987.
26. Magos AL, Brincatt M, Studd JW, et al: Amenorrhea and endometrial atrophy following continuous oral
27. estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 65:496-99, 1985.
28. Charnock-Jones DS, Sharkey AM, Rajput-Williams J, et al: Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and steroid regulation in endometrial carcinoma cell lines. Biol Reprod 48:1120-1128, 1993.
29. Shweiki D, Itin A, Neufeld G, et al: Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 91:2235-2243, 1993.
30. Rogers PAW, Au CL, Affandi B: Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod 9:1396-1404, 1993.
31. Pollard JW, Pacey J, Cheng SVY, et al: Estrogens and cell death in murine uterine luminal epithelium. Cell Tissue Res 249:533-540, 1987.
32. Gu Y, Jow M, Moulton BC, et al: Apoptosis in decidual tissue regression and reorganization. Endocrinology 135:1272-1279, 1994.
33. Moulton BC: Transforming growth factor-beta stimulates endometrial stromal apoptosis in vitro. Endocrinology 134:1055-1060, 1994.
34. Rotello RJ, Lieberman RC, Purchio AF, et al: Coordinated regulation of apoptosis and cell proliferation by transforming growth factor ßl in cultured uterine epithelial cells. Proc Nad Acad Sei USA 88:3412-3415, 1991.
35. Otsuki Y, Misaki O, Sugimoto O, et al: Cyclic be 1-2 gene expression in human uterine endometrium during menstrual cycle. Lancet 344:28-29, 1994.
36. Welsh AO: Uterine cell death during implantation and early placentation. Microscop Res Technique 25:223-245, 1993.